US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Release time：2024-05-22 11:23:48 Source：Global Grid news portal
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
- Previous：North Carolina bill seeks to restrict public and media access to criminal autopsy reports
- Next：The Great British Sewing Bee 2024 cast: Meet the 12 contestants competing in the BBC contest
Related articles
- Diddy's ex
- Video reviews have changed the face of European soccer. One country is holding out
- Video reviews have changed the face of European soccer. One country is holding out
- Kimmich heads Bayern past Arsenal, into UCL semis
- Pogacar extends Giro lead to over 7 minutes after winning altered Stage 16 amid protests at start
- Kimmich heads Bayern past Arsenal, into UCL semis
- New Godzilla x Kong film tops Chinese box office
- Tourism sector sees boom during May Day holiday
- Kentucky congressman expects no voter fallout for his role in attempt to oust House speaker
- Dortmund win six
- Pogacar extends Giro lead to over 7 minutes after winning altered Stage 16 amid protests at start
- California is joining with a New Jersey company to buy a generic opioid overdose reversal drug
- Giant pandas set to travel from China to San Diego Zoo
- Global political party media officials discuss China's modernization
- Vatican makes fresh overture to China, reaffirms that Catholic Church is no threat to sovereignty
- China releases report on global meteorological development in 2023
- Reading campaign launched among college students in China
- China awards medals to Shenzhou
- Austrian leader lauds UK's efforts on migration and cites its plan for deportations to Rwanda
- Hanjiang River in south China sees 3rd flood of 2024
Random recommendation
- Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Global Grid news portal sitemap